Peer reviewed paper ach year, an estimated 250,000 cases of central line associated bloodstream infections occur in hospitals in the United States (CDC, 2005). Reduction of CRBSI has become a major focus for education and initiatives to improve practice. Various antimicrobial agents and practices are supported with evidence to demonstrate impact on CRBSI. The broad spectrum activity of chlorhexidine as an antibacterial, antiviral, and antifungal agent is well accepted (Denton, 2001) .
Introduction
Of the approximately 14 million central venous catheters (CVCs) placed worldwide each year ( Patel et al, 2007 ) , 3-5 % result in a catheter related bloodstream infection (CRBSI) ( Mermel et al, 2001 ) . Studies have shown that between 5 % and 25 % of intravascular (IV) devices are colonised at the time of removal (Safdar and Maki 2002) . Insertion of CVCs is one of the most common invasive procedures performed today. Patients treated with invasive devices are at high risk of acquiring a bloodstream infection because of the migration of skin organisms at the insertion site into the cutaneous tract ( Pearson 1996 ) . Because of the high mortality rates associated with CRBSI (12 % -25 % for each infection) ( Centers for Disease Control, CDC, 2002 ) , preventive strategies are necessary to prevent a CRBSI. Among the strategies found to be successful in reducing CRBSI, the use of chlorhexidine as a skin antiseptic for site preparation has been included in the top fi ve performance indicators for reducing CRBSI recommended by the Centers for Disease Control for skin antisepsis associated with CVCs. The Infusion Nurses Society (INS) Standards of Practice recommends the use of chlorhexidine for central line dressings ( INS, 2006 ) . According to INS, the insertion site is a main portal for organism entry into the venous system and must be protected through initial antimicrobial prepping and maintained with sterile dressing changes that include a transparent dressing changed at least every seven days ( INS, 2006 ) . Prevention of skin fl ora growth has been shown to decrease CRBSI, and chlorhexidine has been shown to reduce skin fl ora growth. The effectiveness of 3M™ Tegaderm™ CHG dressing in preventing CRBSIs has not been studied in a randomised clinical study.
Purpose
The primary purpose of this clinical evaluation was to statistically validate the performance of a new CHG gel dressing in the clinical setting by skilled IV nurses . The secondary objective was to compare the new CHG gel dressing to the CHG dressing currently in use at the study sites. (Safdar, 2005) . Of the approximately 7 million ( Richardson, 2007 ) CVCs placed in the US per year, more than 200,000 resulted in a CRBSI ( Mermel, 2000 ) . The invasive nature of CVC insertion disrupts the integrity of the skin allowing the spread of bacteria along the skin tract into the body and access vessel. Methods to prevent colonisation of skin fl ora around CVC insertion sites, and thus, CRBSI, are important to reduce the morbidity and mortality associated with infection. Chlorhexidine has demonstrated antimicrobial activity for impregnated devices and prepping solutions with effective organism log rhythmic reductions ( Maki et al, 1991 ; Mermel, 2000 ) . The effectiveness of chlorhexidine gluconate as an antiseptic is well known, with broad spectrum activity against Gram-positive and Gram-negative bacteria and yeast. The CDC recommends the use of 2 % chlorhexidine skin preparation for reduction of CRBSI. (CDC, 2002) . Evidence is mounting that the density of skin fl ora at the catheter insertion site is a major risk factor for CRBSI and the majority of CRBSIs originate from the patient's own skin fl ora ( Maki et al, 1977 ) .
Transparent semipermeable dressings have become popular because they protect the insertion site and act as a barrier to external contamination. A new product has been developed that combines the benefi ts of a transparent dressing and a chlorhexidine gel pad. The product is a transparent dressing with an integrated CHG gel pad eliminating the need for a separate chlorhexidine disk.
Study design
Study sites were selected based on current use of a CHG antimicrobial absorptive foam disk (CHG disk). Nurse evaluators used an integrated transparent absorbent CHG gel dressing in place of their current CHG disk plus transparent dressing. Each site participated in the study for a minimum of 14 days. Nurse evaluators completed a written questionnaire at the conclusion of the study.
Facilities and participants
Sixty-four IV nurse evaluators from six hospitals (Table 1 ) participated in this clinical evaluation with a total of 500 new CHG gel dressings applied during the evaluation period.
Data analysis
The sample size for this study was calculated for the primary outcome, overall dressing performance. A 0.5 point difference from a neutral rating ( Table 2 ) was determined to be clinically relevant for the purpose of this calculation. Assuming a standard deviation of 1.0 point, and using an 80 % power of test with a two-sided alpha level of 0.05 with no dropouts, 34 nurse evaluators were calculated to be needed to complete this study.
A one-sample t -test was conducted on the rating scales to test for a signifi cant difference from a neutral rating. For this analysis, the data was coded as shown in Table 1 . The nonparametric Wilcoxon signedrank test was used to confi rm the results. 
Rating value
Much worse (1) −2 Worse (2) −1 Same as (3) 0 Better (4) +1 Much better (5) +2
Results
The new CHG gel dressing rated signifi cantly better than the comparative CHG disk plus transparent dressing in overall performance (p < 0.0001); 90.5 % of evaluators rated the new dressing as equal to, or better than, the comparative dressing. The exact binomial confidence interval was (80.4 % ; 96.4 % ). The new CHG gel dressings were rated signifi cantly better in all dimensions of performance studied (See Table 3 for summary of percentages and Table 4 for mean ratings). All 16 levels of performance were at least the same as, or better than the comparative disk plus transparent dressing, with ratings of 57.1 % or more for better or much better for the CHG gel dressing in comparison with the CHG disk plus transparent dressing. Ability to see through the dressing received the highest average rating with 90.3 % for better or much better accompanied by evaluator comments. Even the lowest rating with the most negative responsesease of removal -was very positive, with 83.6 % rated same as, better or much better.
Performance questions were grouped into four categories: 1) Ease of application, 2) Gel pad performance, 3) Securement function, and 4) Other. In addition, there was a fi nal question based on their clinical experience during the evaluation: 'Would you replace your current antimicrobial dressing (BIOPATCH ® ® and current transparent adhesive dressing (TAD)) with the new Tegaderm ™ CHG dressing?'
Ease of application evaluation
Clinicians performed application of the dressings on patients to evaluate the comparative ease of use between the new CHG gel dressing Peer reviewed paper and the current CHG disk. Four questions incorporated issues of application for the dressing for ease of applying dressing over CVC site, ease with correct application, intuitive to use properly and time in application. For these evaluation points the ratings ranged from 68.8 % to 81 % with better or much better performance and 90.5 % to100 % for same, better or much better, demonstrating a high level of ease in application with the new CHG gel dressing.
Gel pad performance measures
The function of the integrated CHG gel pad was refl ected in fi ve evaluation questions that asked about ability to see the insertion site, ability to absorb fl uid, ability to see after fl uid absorption, moulding and conformity around catheter, and adequacy of gel pad size. The range of results for better and much better were 75.6 % to 90.3 % with all categories exceeding 95 % for same as, better, and much better for the CHG gel dressing than the CHG disk. The ability to visualise the insertion site through the transparent integrated CHG gel dressing rated as the highest performance indicator for the clinical evaluation, with 62.9 % rated as much better than the CHG disk.
Securement function
Indicators for securement focused on the gel conformability reducing movement of the catheter, adherence of the dressing including wear time and overall catheter securement to the skin. The new CHG gel dressing performed well with 66.6 % to 70.6 % for better and much better comparisons. While the greatest majority of evaluators noted ease of use and intuitive placement (94.4 % ), a few (5.6 % ) noted adherence was not comparable with CHG disk and transparent dressing. All facilities used either manufactured securement devices (PICCs) or suture with all CVCs.
Other
Additional areas of performance assessed included ease of dressing removal, adhesive residue on skin or catheter and dressings wasted during application. The majority of evaluators (55.3 % ) indicated that they wasted fewer dressings with the new CHG gel dressing. Most (83.6 % ) found the new dressing to be the same as, better, or much better than the comparator in ease of removal. The adhesive residue on skin or catheter evaluation was rated same as, better, or much better in 85.7 % of the ratings. 'Would you replace your current antimicrobial dressing (BIOPATCH ® and current TAD dressing) with the new Tegaderm ™ CHG dressing?'
Over 85 % of the evaluators (85.9 % ) indicated they would be willing to replace their current dressing with the CHG gel dressing for all PICCs. Non-tunneled subclavian and internal jugular catheters had more than 50 % (58 % and 56.9 % ) with positive agreement to change from current dressing to the evaluation dressing. 
Implications for practice
The clinical evaluation of the CHG gel dressing demonstrated superior performance for intuitive use, ability to see through the dressing, and perceived improved catheter securement. Intuitive use allowed application of this dressing at medical facilities with little training. The post-evaluation review recognised the need to train in the proper application of any transparent adhesive dressing. To achieve the best adherence for TADs, the prep must be allowed to dry and the dressing is applied gently with fi rm pressure. Even without the training, the performance levels were exceptional.
Ability to see through the dressing was not possible with the comparable CHG disk plus transparent dressing, with a resultant inability to see drainage or irritation at the insertion site. Visual inspection of the insertion site is in compliance with best practice guidelines from the CDC and INS Standards and so is desired with all dressings. The CHG gel dressing allowed ease with visual inspection with or without blood or drainage absorption. This feature may result in practice changes that currently indicate a dressing change at 24 hours post-insertion for PICCs, allowing small amounts of blood to be absorbed into the dressing with clear, unobstructed view of the insertion site. CVC dressings still require changes when blood exceeds a small amount although the CHG is not inactivated by blood.
The clinical evaluation also considered the CHG gel dressing as a securement device, measuring performance of adherence, reduction of catheter movement and the ability of the gel pad to mould or conform around the catheter. While performance measured for these functions was above 80 % for same as or better than the current dressing, additional study is needed to determine if this CHG gel dressing provides adequate or better stabilisation without the addition of a manufactured securement device or suture. All CVCs evaluated in this study were secured with sutures or a manufactured securement device.
Conclusion
The CHG dressing provides antimicrobial activity at the insertion site in an integrated dressing that is easy to use. In this evaluation, clinicians perceived a greater level of clinical performance and less chance for application error that would lead to better compliance to established standards of practice. In the past, CHG was only available in prepping agents and the antimicrobial disk such as the one compared in this evaluation. The Tegaderm ™ CHG gel dressing saves application steps and there is no need to carry both an antimicrobial and a transparent dressing.
CVC dressings are changed weekly on average in most facilities. The challenge is to make sure healthcare practitioners provide consistency of care and follow hospital protocol, including sterile technique, while working in a stressful, distracting environment. It is necessary to safeguard central venous access devices from microbial contamination from the patient's own skin fl ora or external contamination. The use of transparent dressings has been accepted in standards of care (i.e CDC Guidelines and INS Standards). The Tegaderm™ CHG dressing provided the benefi t of a transparent dressing and CHG antimicrobial protection with no changes in accepted established clinical practice and adhered to the Standards for need of visualization consistent with CVC assessment and observation evaluations.
